Beyond symptom relief: The promise of Linerixibat as a mechanism-based therapy for cholestatic pruritus in primary biliary cholangitis

Muhammad Hamza Ameer; Muhammad Areeb ul Haq; Menahal Naeem; Abeer Zia; Amna Siddique

doi:10.1016/j.livres.2026.07.002

Liver Research ›› 2026, Vol. 10 ›› Issue (3) :260 -262. DOI: 10.1016/j.livres.2026.07.002

Correspondence

research-article

Beyond symptom relief: The promise of Linerixibat as a mechanism-based therapy for cholestatic pruritus in primary biliary cholangitis

Author information +

History +

PDF (3309KB)

Abstract

Cite this article

Download citation ▾

Muhammad Hamza Ameer, Muhammad Areeb ul Haq, Menahal Naeem, Abeer Zia, Amna Siddique. Beyond symptom relief: The promise of Linerixibat as a mechanism-based therapy for cholestatic pruritus in primary biliary cholangitis. Liver Research, 2026, 10 (3) : 260-262 DOI:10.1016/j.livres.2026.07.002

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of pruritus in primary biliary cholangitis: a narrative review. Am J Med . 2017; 130:744.e1-744.e7. https://doi.org/10.1016/j.amjmed.2017.01.037.

[2]	Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019; 81:1371-1378. https://doi.org/10.1016/j.jaad.2019.04.035.

[3]	GlaxoSmithKline. LYNAVOY (Linerixibat) Tablets: Prescribing Information. GlaxoSmithKline; 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220295Orig1s000lbl.pdf. Accessed 2 July 2026.

[4]	Ebhohon E, Chung RT. Systematic review: efficacy of therapies for cholestatic pruritus. Therapeut Adv Gastroenterol . 2023; 16:17562848231172829. https://doi.org/10.1177/17562848231172829.

[5]	Levy C, Kendrick S, Bowlus CL, et al. GLIMMER: a randomized phase 2b dose—ranging trial of Linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023; 21:1902-1912(e13). https://doi.org/10.1016/j.cgh.2022.10.032.

[6]	Zamek—Gliszczynski MJ, Kenworthy D, Bershas DA, et al. Pharmacokinetics and ADME characterization of intravenous and oral [14C]—Linerixibat in healthy male volunteers. Drug Metab Dispos. 2021; 49:1109-1117. https://doi.org/10.1124/dmd.121.000595.

[7]

Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double—blind, placebo—controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026; 11:22-33. https://doi.org/10.1016/S2468—1253(25)00192—X.